Please assess the completion status of the following clinical trial:

Trial Title: A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older, female, any race~* Histologically diagnosed ovarian cancer, fallopian tube cancer or primary peritoneal cancer~* High grade (or grade 3) serous histology or known to have gBRCAmut~* Has received at least 2 previous courses of platinum-containing therapy, and has disease that was considered platinum sensitive following the penultimate (next to last) platinum course (more than 6 month period between penultimate platinum regimen and progression of disease)~* Has responded to last the platinum regimen, remains in response and is enrolled on study within 8 weeks of completion of the last platinum regimen~* ECOG 0-1~* Adequate bone marrow, kidney and liver function~Exclusion Criteria:~* Known hypersensitivity to the components of niraparib~* Invasive cancer other than ovarian cancer within 2 years (except basal or squamous cell carcinoma of the skin that has been definitely treated)~* Symptomatic uncontrolled brain metastasis~* Is pregnant or breast feeding~* Immunocompromised patients~* Known active hepatic disease~* Prior treatment with a known PARP inhibitor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Niraparib (Type: ACTIVE_COMPARATOR): 2:1 Ratio administered once daily continuously during a 28 day cycle.
- Placebo (Type: PLACEBO_COMPARATOR): Administered once daily continuously over a 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).